FIZE Medical, a Tel Aviv, Israel-based fluid management optimization company, raised $30M in Series A funding.
The round included a $14M Series A-4 led by Rapha Capital Management and its managed fund, Rapha Capital PE Life Sciences Fund VI, with participation from Valitas Venture Capital, and eHealth Ventures.
The company intends to use the funds to expand its geographical reach to the U.S., EU, and Asian markets, and advance its technological development.
Led by CEO Dror Zerem, FIZE Medical is a commercial-stage company. Its FIZE-kUO® device, anchoring the company’s fluid management platform technology, detects early signs of kidney deterioration. Integrated with FIZE’s AI-enabled algorithms, the fluid management technology allows real-time treatment adjustments to prevent long-term kidney damage and improve patient outcomes.
The company is set to soon launch AI-based predictive capabilities that will serve as Decision Support System (DSS) by means of advanced data analysis.
FinSMEs
14/01/2025